<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02825355</url>
  </required_header>
  <id_info>
    <org_study_id>SDUSF12015163 1 (198)</org_study_id>
    <nct_id>NCT02825355</nct_id>
  </id_info>
  <brief_title>Sentinel Node Mapping in Women With Cervical and Endometrial Cancer</brief_title>
  <acronym>SENTIREC I</acronym>
  <official_title>Sentinel Node Mapping With Robotic Assisted Near Infra-red Fluorescent Imaging in Women With Cervical and Endometrial Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Southern Denmark</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Odense University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Danish Cancer Society</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Southern Denmark</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to evaluate the effect of SLN mapping compared to conventional radical PL on
      the incidence and severity of lymphedema in women with early stage cervical and endometrial
      cancer.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 27, 2017</start_date>
  <completion_date type="Anticipated">October 2019</completion_date>
  <primary_completion_date type="Anticipated">October 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of lymphedema</measure>
    <time_frame>3 years</time_frame>
    <description>Incidence of lymphedema will be assessed using patient reported outcome measures.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Severity of lymphedema</measure>
    <time_frame>3 years</time_frame>
    <description>Severity of lymphedema will be assessed using patient reported outcome measures.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Detection rate of sentinel lymph node</measure>
    <time_frame>2 years</time_frame>
    <description>Detection of sentinel lymph node per patient, per heme-pelvis and bilaterally</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mapping of SLN in different types of lymph node stations</measure>
    <time_frame>2 years</time_frame>
    <description>Mapping of SLN in areas outside the normal area of pelvic lymphadenectomy</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">380</enrollment>
  <condition>Uterine Cervical Neoplasms</condition>
  <condition>Uterine Neoplasms</condition>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>The control group will receive conventional treatment, radical pelvic lymphadenectomy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The intervention group will receive sentinel lymph node mapping.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Sentinel lymph node mapping</intervention_name>
    <description>Patients in intervention group will receive sentinel lymph node mapping.</description>
    <arm_group_label>Intervention</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Study IA: Cervical carcinoma, FIGO stage IB1, cervical tumour size &lt; 2 cm

          -  Study IB: Endometrial adenocarcinoma, presumed FIGO stage I, low- and intermediate
             risk: Type 1 grade 1 + 2, &gt; 50% myometrial invasion

        Exclusion Criteria:

          -  Prior PL

          -  Known allergy towards ICG and/or iodine (ICG contains 5% sodium iodine)

          -  Women included in other studies affecting outcome-measures of the present study
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Sara E Sponholtz, MD</last_name>
    <phone>+ 45 28439977</phone>
    <email>sara.elisabeth.sponholtz2@rsyd.dk</email>
  </overall_contact>
  <location>
    <facility>
      <name>Rigshospitalet</name>
      <address>
        <city>Copenhagen</city>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sara E Sponholtz, MD</last_name>
      <phone>+45 28439977</phone>
      <email>Sara.Elisabeth.Sponholtz@rsyd.dk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Herlev Hospital</name>
      <address>
        <city>Herlev</city>
        <zip>2730</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sara E Sponholtz, MD</last_name>
      <phone>+45 28439977</phone>
      <email>Sara.Elisabeth.Sponholtz@rsyd.dk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Odense University Hospital</name>
      <address>
        <city>Odense</city>
        <zip>5000</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sara E Sponholtz, MD</last_name>
      <phone>+45 28439977</phone>
      <email>Sara.Elisabeth.Sponholtz@rsyd.dk</email>
    </contact>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 23, 2016</study_first_submitted>
  <study_first_submitted_qc>July 1, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 7, 2016</study_first_posted>
  <last_update_submitted>March 20, 2017</last_update_submitted>
  <last_update_submitted_qc>March 20, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 22, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Southern Denmark</investigator_affiliation>
    <investigator_full_name>Sara Sponholtz</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>robotic surgery procedure</keyword>
  <keyword>indocyanine green</keyword>
  <keyword>sentinel lymph node mapping</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Endometrial Neoplasms</mesh_term>
    <mesh_term>Uterine Cervical Neoplasms</mesh_term>
    <mesh_term>Uterine Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

